Author

K. M. Shah

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Gartland· 2 shared A. Williamson· 2 shared L. Tattersall· 2 shared A. E. Acosta-Martin· 1 shared A. Hussain· 1 shared A. Singh· 1 shared D. Green· 1 shared D. Heymann· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Gartland

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

P2RX7 inhibition reduces breast cancer induced osteolytic lesions - implications for bone metastasis

K. M. Shah, L. Tattersall, A. Hussain, S. C. Macfarlane, A. Williamson, A. E. Acosta-Martin, J. T. Erler, P. D. Ottewell, A. Gartland

This study shows that inhibiting P2RX7 reduces osteolytic lesions in a murine breast cancer model by increasing cancer cell death and decreasing osteoclast numbers.

bioRxiv · Dec 31, 2021 · PreprintCancer Biology

The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties

L. Tattersall, K. M. Shah, D. L. Lath, A. Singh, J. M. Down, E. De Marchi, A. Williamson, F. Di Virgilio, D. Heymann, E. Adinolfi, W. D. Fraser, D. Green, M. A. Lawson, A. Gartland

This paper shows that the P2RX7B splice variant promotes osteosarcoma metastasis and identifies a novel gene axis inhibited by P2RX7 antagonists.

bioRxiv · May 7, 2021Cancer Biology

Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.

K. Davidson, P. Grevitt, M. Contreras, K. S. Bridge, M. Hermida, K. M. Shah, F. K. Mardakheh, M. Stubbs, P. A. Clarke, R. Burke, P. Casado-Izquierdo, P. R. Cutillas, S. A. Martin, T. V. Sharp

This paper identifies PF-477736 as a selective cytotoxic compound for LIMD1-deficient NSCLC cells and xenograft models, offering a potential targeted therapy for this understudied cancer subtype.

bioRxiv · Feb 1, 2021Cancer Biology